CM8® is short for Cetyl Myristoleate. Cetyl Myristoleate is an all-natural compound useful for arthritis and joint pain relief. Cetyl Myristoleate is clinically shown to treat and even prevent joint pain, arthritis, osteoarthritis, rheumatoid arthritis (RA), gout and fibromyalgia.
The name Cetyl Myristoleate describes the chemical makeup of CM8®. It is the cetyl ester of myristoleic acid. CM8® has numerous biological functions, including working as an anti-inflammatory agent and a pain reliever. It also performs well as an immune system modulator. It is naturally derived and highly purified. When refined for oral ingestion it is a waxy ester. Because CM8® is in an ester form, it is highly resistant to oxidation and has a relatively long life in the body.
The Cetyl Myristoleate Complex is the final result of years of clinical research, exploration and testing of various raw materials, unique isolation techniques, and countless hours of investigating optimum delivery systems. It is traditionally concentrated into a fine powder for capsuling or tableting.
The Functions of CM8®
Cetyl Myristoleate functions primarily in four ways:
- One of the first observations noted when taking Cetyl Myristoleate is the lubricating qualities it possesses. Decrease or loss of morning stiffness is commonly noted shortly after commencing treatment.
- It functions as an anti-inflammatory agent. Lessening of swollen areas is usually observed as early as the second or third week of treatment.
- It works as an immune system modulator. Its ability to regulate or quell hyper-immune responses is the most exciting quality and should be included in any program addressing autoimmune diseases.
- Finally, CM8® functions as an analgesic, or pain killer. The decrease in pain results from the decrease in inflammation which is often the culprit of joint and muscle pain.
The Story of CM8®
Cetyl Myristoleate Developed at the National Institute of Health
For over 40 years, Dr. Harry Diehl dedicated his service to the US government working for the prestigious National Institutes of Health (NIH) in the Laboratory of Chemistry of the National Institute of Arthritis, Metabolic, and Digestive Diseases located in Bethesda, Maryland. In 1964, at the age of 40, Dr. Diehl became concerned about a neighbor’s pain and disability from rheumatoid arthritis. The friend’s condition had deteriorated over time until he became disabled. The neighbor had a family to support, but his arthritis had made that impossible. Diehl was a deeply religious man whose feelings overwhelmed him as his friend’s condition worsened. Harry thought, “Here I am working for the US Government at the National Institutes of Health, and I have never seen anything that was good for curing arthritis.” He decided to take the initiative to establish a laboratory in his home to embark on a search for something to relieve the pain and disability of his neighbor and the millions of people who suffer from arthritis.
As a researcher, Diehl knew that finding a cure for arthritis meant inducing the disease experimentally in research animals. He started with albino mice and quickly realized that he was unable to induce arthritis in them. Diehl said he tried every way he could to give the mice arthritis, but they just would not get it. Then, he wrote to a fellow researcher in California, “If you or anyone else can give mice arthritis, I want to know about it, because mice are 100% immune to arthritis.” At that moment, Diehl’s research instincts told him that what he wanted was already somewhere in those mice.
Cetyl Myristoleate (CM8®) Development Methodology
Utilizing thin layer chromatography of methylene chloride extract from macerated mice, Diehl noticed a mysterious compound. It was a long, tedious job, working in his spare time, but Diehl finally found, isolated, and identified the extract. It was Cetyl Myristoleate – and it protected mice from arthritis. Now having isolated the compound, Dr. Diehl went about the molecular recreation of it. This meant that rather than destroying mice to get a quantity of this amazing molecule, Harry learned to synthesize it in the laboratory. Cetyl Myristoleate could be made synthetically by chemically combining cetyl alcohol, with myristoleic acid and he found that this form of Cetyl Myristoleate was just as effective in providing rats immunity to adjuvant-induced arthritis as the naturally occurring form (extracted from mice).
To test his theory that mice are immune to arthritis because of Cetyl Myristoleate, Diehl began to experiment on laboratory rats. Harry injected it into two groups of rats that he knew developed arthritis when injected with Freund’s adjuvant. He was pleased to find that the group of rats also injected with Cetyl Myristoleate remained arthritis-free, and grew an average of 5.7 times as much as the control group that was not given the Cetyl Myristoleate, which had in fact developed arthritis. This research was reported in an article written in conjunction with one of his colleagues at NIH in the Journal of Pharmaceutical Sciences.
Cetyl Myristoleate (CM8®) Findings Proven & Published
Diehl’s research on Cetyl Myristoleate was published in the March 1994 issue of The American Journal of Pharmaceutical Sciences, the prestigious peer-reviewed journal, American Pharmaceutical Association, and also The American Chemical Society (VOL 83, #3, March 1994, pages 296-299). Dr. Diehl was granted three U.S. patents for Cetyl Myristoleate and its usage, the first in 1977 on Cetyl Myristoleate, the second in 1978 for its treatment of rheumatoid arthritis and the third in 1996 for its treatment of osteoarthritis.
After receiving his first patent, Diehl approached the pharmaceutical industry with his amazing discovery. Unfortunately, none of the pharmaceutical companies were interested, primarily because Cetyl Myristoleate is a natural substance and cannot be granted a “product” patent. To pharmaceutical companies this meant a lack of exclusivity which diminishes the potential to make billions of dollars. Being a scientist not a salesperson, Dr. Diehl didn’t know of another way to expose Cetyl Myristoleate to the public. Consequently, his discovery was not utilized until 1991 when he developed arthritis himself.
As Diehl aged, he could feel the arthritis in his hands, knees and heels of his feet. His physician prescribed the usual regimen of cortisone and non-steroidal anti-inflammatory drugs, which had little or no effect on the disease. When Diehl’s doctor told him he could not undergo anymore cortisone it prompted him to think about his discovery. He then decided to reproduce the compound for his own personal use.
Dr. Diehl took Cetyl Myristoleate and the symptoms of his osteoarthritis disappeared. His family members and friends observed his rapid recovery and they became interested in it too. Those close to Diehl tried Cetyl Myristoleate and were amazed by the relief they too received from rheumatoid and osteoarthritis. Before long, these people grew into loyal customers, spreading the word of Diehl’s discovery. In 1991, Dr. Diehl’s discovery made its debut as a dietary supplement.
A Recent Clinical Study
(The following is a summary of one recent clinical study. There have been other studies conducted around the efficacy of the ingredients contained in Flexcin’s ® proprietary formula. For a complete listing of references, see the footnotes below.)
A multi-center, clinical research study was recently conducted by Dr. H. Siemandi, M.D., Ph.D. in California, involving 382 patients who were diagnosed with degenerative joint disease, rheumatoid arthritis or psoriatic arthritis.
Each patient was evaluated on function/mobility according to the following established measurement criteria:
- Joint swelling
- Joint pain
- Chest expansion
- Blood analysis
- Radiographic assessment
- Patient assessment
- Physician assessment
The objective of this study was to compare the efficacy and safety of joint treatment by an oral-based Cetyl Myristoleate complex versus a placebo in test subjects. The study was performed as a randomized, double-blind, placebo-controlled parallel trial. The patients were divided into three groups and tested over a 30 day period.
The first group (A) received a complex of fatty acids containing Cetyl Myristoleate (similar to the bio-enriched form found in Flexcin®).
The second group (B) received the same Cetyl Myristoleate complex plus Glucosamine hydrochloride, sea cucumber and hydrolyzed cartilage(even more similar, but still less effective derivatives of the proprietary ingredients present in Flexcin®).
The third group (C) received a placebo.
At the conclusion of the study, the outcome measures included patient-reported, clinical, laboratory and radiograph assessments.
The astounding results were recorded in theTownsend Letter for Doctors and Patients and are reproduced here (reported in percentage of improvement):
|Group A||Group B||Group C|
|M.D. Overall Assessment||58.1%||84.2%||13.9%|
|Patient Overall Assessment||59.2%||88.2%||16.1%|
|Joint Swelling Score||47.5%||77.2%||21.1%|
The remarkable results showed a significant improvement of 63.3% in Group A, which received Cetyl Myristoleate alone. In Group B, the addition of complimentary elements, (creating an enhanced Cetyl Myristoleate based complex) resulted in an even more astonishing improvement, averaging over 84%. Group C, the placebo group, reported just a 14.5% improvement.
To fully appreciate the astounding results of this study, let’s compare it to test results from two common prescription drugs. As discussed in Arthritisin the Johns Hopkins White Papers (Simeon, Margolis, M.D., PhD, and John A. Flynn, M.D.), two drugs commonly used to treat rheumatoid arthritis in those who do not respond to non-steroidal anti-inflammatory drugs (NSAIDs) are methotrexate and cyclosporin.
One study showed that when taken together, these two drugs proved to be only 20% effective in relieving the symptoms of rheumatoid arthritis. Those taking methotrexate alone saw only 16% improvement. Methotrexate has been shown to harm the liver. Biopsies (removing a piece of the liver) are routinely recommended for patients taking this medication to monitor liver damage. Blood tests are also performed every 4-8 weeks while taking these drugs to assess any possible harm.
As you can see from the comparison alone, the Cetyl Myristoleate complex group (Group B) experienced a rate of improvement nearly 70% higher than those treated with more traditional drugs. The significant results of this clinically-validated study attest to the efficacy of Flexcin®, whose proprietary formula actually contains an even more potent formulation than what the Cetyl Myristoleate complex group (Group B) received.